Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMC-Alemtuzumab in T-cell Prolymphocytic Leukemia
NCT01186640Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jun 2010
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in T-cell prolymphocytic leukemia (T-PLL), sponsored by German CLL Study Group. Started Jun 2010; status: completed.
02
Drugs
alemtuzumab
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT01186640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186640.